News & Announcements

​Concerning Variants of SARS-CoV-2

Article from 2021-01-25


Over time, new variants of a virus are expected to occur as all viruses constantly mutate their genetic code. These variants can emerge and disappear spontaneously, though sometimes selective pressure allows the variant to persist through adaptive evolution. Multiple variants of the SARS-CoV-2 virus that causes COVID-19 have been documented globally. The first emerging concern was a variant originating in the United Kingdom with an unusually large number of mutations. 

Lineage B.1.1.7 (known as Alpha, 20B/501Y.V1, or VOC 202012/01, which indicates the first variant of concern in December 2020) carries 23 mutations compared to the wild-type SARS-CoV-2. This includes 14 non-synonymous (amino acid altering) mutations, six synonymous (non-amino acid altering) mutations, and three deletions (Table 1).1,2 17 of these mutations lead to changes in protein structures, eight of which occur in the spike protein (Figure 1). This is highly unprecedented as most SARS-CoV-2 variants have only a few mutations that accumulate at a relatively consistent rate over time (~1-2 per month).

Table 1. Amino Acid Substitutions and Deletions in B.1.1.7 (Alpha) Lineage

Protein Amino Acid
ORF1ab 
T1001I
A1708D
I2230T
SGF 3675-3677 deletion
C913T
C5986T
C14676T
C15279T
C16176T
Spike H69-V70 deletion
Y144 deletion
N501Y
A570D
P681H
T716I
S982A
D1118H
ORF8 Q27stop
R52I
Y73C
N
D3L
S235F
M T26801C



Figure 1. Compilation of SARS-CoV-2 spike mutations occurring in the new UK, South African, Brazilian, and Indian variants as indicated in the inset.
NTD: N-terminal domain. RBD: Receptor binding domain.


One of the most important changes in B.1.1.7 is a mutation in the receptor binding domain (RBD) of the spike protein at position 501, where asparagine has been replaced with tyrosine (N501Y). According to prior work on variants with N501Y, this substitution is thought to increase the affinity of the spike protein for the angiotensin-converting enzyme 2 (ACE2) receptor on human cells, its entry point for infection.3 Indeed, the B.1.1.7 variant is estimated to be 74% more transmissible than the wild type and was projected to become the dominant source of infection in the US by March 2021.

Other notable mutations in the B.1.1.7 variant include a double deletion of the amino acids in positions H69-V70 in the N-terminal domain of the spike protein that likely leads to a conformational change in the spike protein. This particular mutation has also been found in coronaviruses that eluded the immune response in some immunocompromised patients and appeared in infected mink in Denmark in August 2020.4 A study from the University of Cambridge has suggested this mutation increases infectivity two-fold in in vitro experiments and may make neutralizing antibodies less effective.5

A P681H mutation occurs at one of the four residues that comprise the insertion that creates a furin cleavage site between S1 and S2 in the spike protein. This site, which facilitates viral membrane fusion to host cells, has been shown to promote entry into respiratory epithelial cells and transmission in animal models.6-8

The function of a stop codon (Q27stop) added to the open reading frame 8 (ORF8) that renders it inactive is not completely known and may allow further downstream mutations to accrue. This gene is hypervariable with a tendency to recombine and undergo deletions that facilitate viral adaptation to the human host. The ORF8 gene encodes for an immunoglobulin-like protein that was recently found to inhibit the presentation of viral antigens by class I major histocompatibility complex, suppress the type I interferon antiviral response, and interact with host factors involved in pulmonary inflammation and fibrogenesis.9 A full deletion of ORF8 in a variant identified in Singapore has been associated with milder COVID-19 symptoms and better disease outcome.10

In South Africa, another variant of SARS-CoV-2 (known as Beta, 20C/501Y.V2 or B.1.351 lineage) emerged independently of the B.1.1.7 lineage. This variant has eight defining mutations in the spike protein including K417N, E484K, and N501Y substitutions in the spike protein RBD that increase affinity for the ACE2 receptor (Table 2, Figure 1).11,12 Although it contains the N501Y mutation found in the B.1.1.7 variant, it does not contain the deletion at H69-V70. The E484K mutation has been associated with escape from neutralizing antibodies.13

Table 2. Amino Acid Substitutions and Deletions in B.1.351 (Beta) Lineage

Protein Amino Acid
Spike  
L18F
D80A
D215G
L242_244L (disputed deletion)
R246I
K417N
E484K
N501Y
A701V

 

Circulating in the Brazilian Amazon region, a branch off the SARS-CoV-2 B.1.1.28 lineage termed P.1 (Gamma or 20J/501Y.V3) includes several mutations of known biological importance such as E484K, K417T, and N501Y in the RBD of the spike protein but is of independent origin from B.1.1.7 and B.1.351.14 This variant has ten defining mutations in the spike protein (Table 3, Figure 1).15 The B.1.1.28 variant was associated with two cases of reinfection in patients originally infected by the Brazilian B.1.1.33 lineage, and the P.1 variant was identified in Japan from travelers returning from northern Brazil.14,16

Table 3. Amino Acid Substitutions, Insertions, and Deletions in P.1 (Gamma) Lineage

Protein Amino Acid
ORF1ab

SynT733C
SynC2749T
S1188L
K1795Q
Del11288-11296 (SGF 3675-3677 deletion)
SynC12778T
SynC13860T
E5665D
Spike
L18F
T20N
P26S
D138Y
R190S
K417T
E484K
N501Y
H655Y
T1027I
ORF8
E92K
Ins28269-28273
N P80R

 

A variant from India, designated as B.1.617.2 or Delta, is now the predominant variant in the US, according to estimates by the CDC (Table 4, Figure 1). A structural analysis of B.1.617.2 RBD mutations (L452R along with P681R in the furin cleavage site) suggest that these mutations may result in increased ACE2 binding and rate of S1-S2 cleavage, resulting in better transmissibility and possible capacity to escape binding and neutralization by some monoclonal antibodies.17 A mutation of this variant, called Delta plus, has acquired the spike protein mutation K417N in the RBD that in other variants has been shown to increase affinity for the ACE2 receptor.

Table 4. Amino Acid Substitutions and Deletion in B.1.617.2 (Delta) Lineage

B.1.617.2

Protein Amino Acid
Spike
T19R
G142D
Del156-157
R158G
L452R
T478K
D614G
P681R
D950N


The simultaneous emergence of different SARS-CoV-2 lineages from different countries around the world each carrying mutations in the spike protein receptor binding site reveal convergent selective pressure on SARS-CoV-2 to create an advantage towards its transmissibility and reinfection of individuals. This is a major concern as these mutations may evolve to escape neutralizing antibodies. Cayman is monitoring the rapidly emerging information on these variants and offers structure-based design services (SBDD) for macromolecular X-ray crystallography and computer-aided drug design services (CADD) for in silico screening of drug candidates that target the SARS-CoV-2 spike protein.

You Might Also Be Interested In


Cayman Currents Issue 33: Antiviral Strategies for Emerging Infectious Diseases


Using Existing Therapeutics Against SARS-CoV-2

tools-to-study-470x150.png
Tools to Study SARS-CoV-2-Host Interactions


 

Explore more coronavirus research tools, literature, and resources


References

1. Rambaut, A., Loman, N., Pybus, O., et al. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. In: virological.org [Internet]. (2020). Available from: https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563

2. Gu, H., Chen, Q., Yang, G., et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science 369(6511), 1603-1607 (2020).

3. Starr, T.N., Greaney, A.J., Hilton, S.K., et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell 182(5), 1295-1310 (2020).

4. Kemp, S.A., Datir, R.P., Collier, D.A., et al. Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion ΔH69/ΔV70. bioRxiv 2020.12.14.422555 (2020).

5. Kemp, S.A., Collier, D.A., Datir, R., et al. Neutralising antibodies drive spike mediated SARS-CoV-2 evasion. medRxiv 2020.12.05.20241927 (2020).

6. Hoffmann, M., Kleine-Weber, H., and Pöhlmann, S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol. Cell 78(4), 779-84 (2020).

7. Peacock, T.P., Goldhill, D.H., Zhou, J., et al. The furin cleavage site of SARS-CoV-2 spike protein is a key determinant for transmission due to enhanced replication in airway cells. bioRxiv 2020.09.30.318311 (2020).

8. Zhu, Y., Feng, F., Hu, G., et al. The S1/S2 boundary of SARS-CoV-2 spike protein modulates cell entry pathways and transmission. bioRxiv 2020.08.25.266775 (2020).

9. Zinzula, L. Lost in deletion: The enigmatic ORF8 protein of SARS-CoV-2. Biochem. Biophys. Res. Commun. (2020).

10. Young, B.E., Fong, S.-W., Chan, Y.-H., et al. Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: An observational cohort study. Lancet 396(10251), 603-611 (2020).

11. Pond, S.L.K., Wilkison, E., Weaver, S., et al. A preliminary selection analysis of the South African V501.V2 SARS-CoV-2 clade. In: virological.org [Internet]. (2020). Available from: https://virological.org/t/a-preliminary-selection-analysis-of-the-south-african-v501-v2-sars-cov-2-clade/573

12. Tegally, H., Wilkinson, E., Giovanetti, M., et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv 2020.12.21.20248640 (2020).

13. Greaney, A.J., Starr, T.N., Gilchuk, P., et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe 29(1), 44-57 (2021).

14. Faria, N.R., Claro, I.M., Candido, D., et al. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: Preliminary findings. In: virological.org [Internet]. (2021). Available from: https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586

15. Pond, S.L.K., Wilkison, E., Weaver, S., et al. Phylogenetic relationship of SARS-CoV-2 sequences from Amazonas with emerging Brazilian variants harboring mutations E484K and N501Y in the Spike protein. In: virological.org [Internet]. (2021). Available from: https://virological.org/t/phylogenetic-relationship-of-sars-cov-2-sequences-from-amazonas-with-emerging-brazilian-variants-harboring-mutations-e484k-and-n501y-in-the-spike-protein/585

16. Resende, P.C., Bezerra, J.F., de Vasconcelos, R.H.T., et al. Spike E484K mutation in the first SARS-CoV-2 reinfection case confirmed in Brazil, 2020. In: virological.org [Internet]. (2021). Available from: https://virological.org/t/spike-e484k-mutation-in-the-first-sars-cov-2-reinfection-case-confirmed-in-brazil-2020/584

17. Cherian, S., Potdar, V., Jadhav, S., et al. Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. bioRxiv (2021).


Receive Our News & Literature Directly to Your Inbox!

Log in or register to subscribe to our email list. You will receive emails packed with new products and content that match your research interests. We only email once a week and you can unsubscribe at any time.